| Name | Decamethonium bromide |
| Description | Decamethonium bromide (Syncurine) is a neuromuscular blocker and nicotinic AChR partial agonist. |
| In vivo | At the motor neuromuscular endplate, Decamethonium induces a depolarization that prevents the normal release of acetylcholine from presynaptic terminals from acting further, thereby preventing the nerve stimulus from affecting the muscle. During binding, Decamethonium actually activates (depolarizes) the motor endplate, but does not degrade itself, so the cell membrane remains depolarized and unresponsive to normal acetylcholine release. As a depolarizing muscle relaxant or neuromuscular blocker, Decamethonium is used in anesthesia to induce paralysis. It has a short duration of action similar to that of acetylcholine and acts as a partial agonist at nicotinic acetylcholine-like receptors. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.78 mM), Sonication is recommended.
H2O : 77 mg/mL (184.08 mM), Sonication is recommended.
DMSO : 65 mg/mL (155.39 mM), Sonication is recommended.
Ethanol : 24 mg/mL (57.38 mM), Sonication is recommended.
|
| Keywords | Nicotinic acetylcholine receptors | nAChR | Inhibitor | inhibit | Decamethonium bromide | Decamethonium | AChE |
| Inhibitors Related | Adiphenine hydrochloride | Levamisole hydrochloride | Urethane | Ribavirin | Diethyltoluamide | Adenine | Mitotane | N,N-Dicyclohexylcarbodiimide | Dimethyl sulfoxide | Coumaran | Arecoline | Trimethylammonium chloride |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
United States
